Background
Plague is an infectious disease caused by Yersinia pestis, a naturally occurring bacterium found primarily in wild rodents. Plague has been the cause of 3 of the great pandemics of the modern era-in the mid-6th century, the mid-14 th century (known as the Black Death), and the early 20 th century.
Three forms of naturally occurring plague infection exist:
• Pneumonic plague is the result of Y. pestis infection of the lungs. Primary pneumonic plague results from inhalation of Y. pestis bacteria and would be the expected form of disease following an aerosol attack with Y. pestis. Secondary pneumonic plague can occur if bubonic or septicemic plague goes untreated and the plague bacteria are allowed to spread to the lungs.
• Bubonic plague is the most common form of naturally occurring plague and is typically acquired through the bite of an infected flea. Bubonic plague is characterized primarily by swollen, tender lymph nodes (called buboes).
• Septicemic plague is the result of plague bacteria multiplying in the blood and disseminating throughout the body. Septicemic plague usually occurs as a result of untreated bubonic or pneumonic plague.
Plague is recognized by public health experts as a re-emerging infectious disease. Worldwide incidence has reached approximately 2,000 to 3,000 reported cases each year. 
Plague as a Biological Weapon
Plague is currently considered to be one of the most serious bioterrorism threats. Y. pestis was developed as an aerosol weapon by several countries in the past. Aerosol dissemination of bacteria would cause primary pneumonic plague in the exposed population, an otherwise uncommon, highly lethal, and contagious form of plague.
A number of factors contribute to concern over the use of plague as a biological weapon:
• There is widespread availability of Y. pestis in microbe banks around the world.
• There is widespread natural availability of the Y. pestis bacteria in endemic areas
• Reports indicate that techniques for mass production and aerosol dissemination of Y. pestis have been developed.
• The fatality rate of pneumonic plague in untreated cases is extremely high.
• Plague has the potential for secondary spread from person to person following an attack.
• Y. pestis can be disseminated in aerosol form.
• Plague has a low infectious dose.
• Antibiotic resistant strains of Y. pestis exist in nature.
A 1970 World Health Organization (WHO) assessment asserted that in a worst-case scenario a dissemination of 50 kg of Y. pestis in an aerosol cloud over a city of 5 million might result in 150,000 cases of pneumonic plague. Of those, 80,000 to 100,000 cases would require hospitalization, and 36,000 victims would be expected to die. (See "The History of Bioterrorism: Plague," a short video from the CDC, available at http://www.bt.cdc.gov/training/historyofbt/03plague.asp)
Signs and Symptoms
Diagnosis of plague is based on clinical presentation of symptoms and confirmed by laboratory testing, which usually takes 24 to 48 hours. There are no widely available rapid diagnostic tests for plague. The first sign of a bioterrorist attack with plague would most likely be a sudden surge of patients presenting at hospitals and doctors' offices with symptoms of severe pneumonia and sepsis.
Transmission
Fleas are natural vectors (carriers) of Y. pestis, and the bacteria are typically transmitted to and among rodents via flea bite. Humans may contract plague through a flea bite or by handling an infected animal or breathing in an aerosolized form of the bacteria.
Neither bubonic or septicemic plague are known to spread directly from person to person. However, pneumonic plague does spread from person to person through respiratory droplets over short distances.
Infection Control Measures
The Centers for Disease Control and Prevention (CDC) recommends that individuals suspected of having pneumonic plague be placed in isolation, with respiratory droplet precautions, and monitored for symptoms for the first 48 hours of antibiotic treatment. Those with confirmed pneumonic plague should remain in isolation under droplet precautions until all laboratory cultures are negative, indicating that disease has run its course. Standard respiratory droplet precautions should also be taken by individuals in close contact with patients with confirmed or suspected pneumonic plague.
Contacts of patients with plague should be identified for surveillance purposes, and any contacts who develop plague should be placed in isolation.
Treatment and Prophylaxis
Early antibiotic therapy is recommended for persons deemed exposed to or infected with plague. Tetracyclines (eg, doxycycline), fluoroquinolones (eg, ciprofloxacin), and aminoglycosides (eg, streptomycin, although not widely available, and gentamicin) are all antibiotics that have been used for post-exposure prophylaxis and treatment of plague. Specific treatment recommendations following a biological attack with plague will depend on several factors, including antibiotic susceptibility of the strain.
Antibiotic treatment should be initiated within 24 hours for patients showing symptoms of pneumonic infection, and should be continued for 10 days. Prophylactic antibiotics may be administered to protect people who have had known direct contact with infected patients, and should be continued for 7 days. People with suspected exposure to pneumonic plague should be placed under surveillance and monitored for symptoms. If symptoms develop, antibiotic therapy should be initiated immediately and continued for 10 days. In addition to antibiotic prophylaxis, people with established ongoing exposure to a patient with pneumonic plague should use standard respiratory droplet precautions.
Countermeasures
A vaccine for plague is not currently available for civilian use in the United States. A U.S. licensed vaccine exists, but it is no longer commercially available. This vaccine has some efficacy in preventing or lessening the severity of bubonic disease in a preexposure setting; however, it has not been shown to be effective in preventing pneumonic plague.
Research and development efforts for both an attenuated live vaccine and a subunit vaccine that protects against pneumonic plague are ongoing.
Additionally, a number of promising new antibiotics and intervention strategies have yet to be fully explored experimentally.
Clinical Presentation of Plague

Plague Infection Incubation Period Signs and Symptoms Lethality
Pneumonic 2 to 4 days (range 1 to 6 days) after exposure
The first signs are fever, cough, muscle aches, and headache, with progression to chest pain, difficulty breathing, and hemoptysis (coughing blood). Nausea, vomiting, and abdominal pain might also occur.
Pneumonic plague is highly lethal when untreated or when antibiotic treatment is started more than 24 hours after the onset of symptoms. Untreated, the fatality rate of pneumonic plague approaches 100%.
Bubonic 1 to 8 days following exposure to an infected animal or sustaining a flea bite Sudden onset of fever, chills, weakness, headache, and buboes will occur, typically followed by nausea and vomiting. The bubo is an extremely painful bump resulting from a swollen, tender lymph node, usually in the groin, armpit, or neck.
Without prompt treatment, or if left untreated, bubonic plague has a fatality rate of 50% to 60%.
Septicemic
Untreated, bubonic or pneumonic plague may develop into septicemic infection 2 to 6 days after initial symptoms appear.
Fever, chills, abdominal pain, nausea, vomiting, diarrhea. Later, this infection may lead to coagulation problems and gangrene of the extremities.
Without prompt treatment, or if left untreated, the fatality rate of septicemic plague approaches 100%.
